Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells $37,363.60 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the transaction, the insider now owns 92,260 shares in the company, valued at approximately $535,108. The trade was a 6.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Linda Llewelyn also recently made the following trade(s):

• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The stock was sold at an average price of $7.88, for a total value of $50,762.96.

Health Catalyst Trading Down 0.2 %

NASDAQ HCAT opened at $5.49 on Monday. The business’s fifty day moving average is $7.56 and its 200-day moving average is $7.52. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $334.07 million, a price-to-earnings ratio of -4.07 and a beta of 1.36. Health Catalyst, Inc. has a one year low of $5.35 and a one year high of $10.99.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. Equities research analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Evercore ISI boosted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Royal Bank of Canada dropped their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.27.

Hedge Funds Weigh In On Health Catalyst

Institutional investors and hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the last quarter. Millennium Management LLC lifted its holdings in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares during the last quarter. Nepsis Inc. boosted its position in Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares during the period. Fred Alger Management LLC purchased a new position in shares of Health Catalyst in the third quarter worth about $6,858,000. Finally, Portolan Capital Management LLC bought a new stake in shares of Health Catalyst in the third quarter valued at approximately $5,402,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.